BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 517 filers reported holding BIO-TECHNE CORP in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $50,182,495 | -14.8% | 737,219 | +2.2% | 0.09% | -12.6% |
| Q2 2023 | $58,903,417 | +17.7% | 721,586 | +7.0% | 0.10% | +10.8% |
| Q1 2023 | $50,046,384 | -36.0% | 674,567 | -28.5% | 0.09% | -46.6% |
| Q4 2022 | $78,212,104 | +3.0% | 943,691 | +253.1% | 0.17% | +3.0% |
| Q3 2022 | $75,902,000 | -18.1% | 267,262 | -0.1% | 0.17% | -15.5% |
| Q2 2022 | $92,657,000 | -8.6% | 267,484 | +14.3% | 0.20% | -2.0% |
| Q1 2022 | $101,331,000 | -14.7% | 234,107 | +2.0% | 0.20% | -8.5% |
| Q4 2021 | $118,848,000 | +29.4% | 229,593 | +21.1% | 0.22% | +15.5% |
| Q3 2021 | $91,826,000 | -2.7% | 189,636 | -9.5% | 0.19% | -7.7% |
| Q2 2021 | $94,410,000 | +11.3% | 209,655 | -5.8% | 0.21% | -2.3% |
| Q1 2021 | $84,841,000 | +33.0% | 222,543 | +10.8% | 0.21% | +29.7% |
| Q4 2020 | $63,789,000 | +20.5% | 200,877 | -6.1% | 0.16% | +7.8% |
| Q3 2020 | $52,954,000 | -11.3% | 213,845 | -5.4% | 0.15% | -17.3% |
| Q2 2020 | $59,695,000 | +36.1% | 225,957 | -2.3% | 0.18% | +14.9% |
| Q1 2020 | $43,852,000 | -16.0% | 231,261 | -2.7% | 0.16% | +3.2% |
| Q4 2019 | $52,176,000 | +10.6% | 237,588 | -1.4% | 0.16% | +28.9% |
| Q3 2019 | $47,169,000 | -7.9% | 241,070 | -1.9% | 0.12% | -27.5% |
| Q2 2019 | $51,204,000 | +3.4% | 245,631 | -1.6% | 0.17% | +0.6% |
| Q1 2019 | $49,535,000 | +36.2% | 249,558 | +39.0% | 0.17% | +28.7% |
| Q4 2018 | $36,365,000 | +1.4% | 179,486 | +2.1% | 0.13% | -0.8% |
| Q3 2018 | $35,880,000 | +36.7% | 175,855 | -0.9% | 0.13% | +46.1% |
| Q2 2018 | $26,243,000 | -0.4% | 177,374 | +1.7% | 0.09% | -11.9% |
| Q1 2018 | $26,338,000 | -13.3% | 174,377 | -25.6% | 0.10% | -3.8% |
| Q4 2017 | $30,378,000 | +6.8% | 234,488 | -0.3% | 0.10% | +4.0% |
| Q3 2017 | $28,436,000 | +3.0% | 235,220 | +0.1% | 0.10% | -8.2% |
| Q2 2017 | $27,617,000 | +20.2% | 235,036 | +4.0% | 0.11% | +8.9% |
| Q1 2017 | $22,976,000 | +6.5% | 226,032 | +7.7% | 0.10% | -3.8% |
| Q4 2016 | $21,583,000 | -5.7% | 209,896 | +0.4% | 0.10% | -9.5% |
| Q3 2016 | $22,892,000 | -11.0% | 209,063 | -8.3% | 0.12% | -24.7% |
| Q2 2016 | $25,711,000 | +21.5% | 227,998 | +1.9% | 0.15% | +16.7% |
| Q1 2016 | $21,153,000 | +2.0% | 223,795 | -2.9% | 0.13% | +4.8% |
| Q4 2015 | $20,732,000 | +144.5% | 230,361 | +151.1% | 0.13% | +61.5% |
| Q3 2015 | $8,481,000 | -12.7% | 91,735 | -7.0% | 0.08% | -11.4% |
| Q2 2015 | $9,710,000 | +0.8% | 98,606 | +2.7% | 0.09% | +4.8% |
| Q1 2015 | $9,636,000 | +8.8% | 96,054 | +0.2% | 0.08% | +7.7% |
| Q4 2014 | $8,854,000 | – | 95,819 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ownership Capital B.V. | 972,263 | $308,742,000 | 4.35% |
| Sandhill Capital Partners LLC | 138,864 | $44,096,000 | 4.03% |
| STONE RUN CAPITAL, LLC | 27,350 | $8,685,000 | 3.45% |
| DF DENT & CO INC | 925,823 | $293,995,000 | 3.42% |
| Brown Capital Management | 1,498,233 | $475,764,000 | 3.29% |
| MAIRS & POWER INC | 848,081 | $269,308,000 | 2.99% |
| Summit Creek Advisors LLC | 64,179 | $20,380,000 | 2.62% |
| GENEVA CAPITAL MANAGEMENT LLC | 402,958 | $127,959,000 | 2.17% |
| Aristotle Atlantic Partners, LLC | 86,993 | $27,625,000 | 2.13% |
| CROWN ADVISORS MANAGEMENT, INC. | 8,000 | $2,540,000 | 1.82% |